163 related articles for article (PubMed ID: 21417439)
21. Survivin siRNA increases sensitivity of primary cultures of ovarian cancer cells to paclitaxel.
Kar R; Palanichamy JK; Banerjee A; Chattopadhyay P; Jain SK; Singh N
Clin Transl Oncol; 2015 Sep; 17(9):737-42. PubMed ID: 26033427
[TBL] [Abstract][Full Text] [Related]
22. Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer.
Salzano G; Riehle R; Navarro G; Perche F; De Rosa G; Torchilin VP
Cancer Lett; 2014 Feb; 343(2):224-31. PubMed ID: 24099916
[TBL] [Abstract][Full Text] [Related]
23. [Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel].
Yan XJ; Liang LZ; Zeng ZY; Shi Z; Fu LW
Ai Zheng; 2006 Apr; 25(4):398-403. PubMed ID: 16613669
[TBL] [Abstract][Full Text] [Related]
24. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
[TBL] [Abstract][Full Text] [Related]
25. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
[TBL] [Abstract][Full Text] [Related]
26. Oxaliplatin-mediated inhibition of survivin increases sensitivity of head and neck squamous cell carcinoma cell lines to paclitaxel.
Khan Z; Khan N; Varma AK; Tiwari RP; Mouhamad S; Prasad GB; Bisen P
Curr Cancer Drug Targets; 2010 Nov; 10(7):660-9. PubMed ID: 20578991
[TBL] [Abstract][Full Text] [Related]
27. Ultrasound-Guided Delivery of siRNA and a Chemotherapeutic Drug by Using Microbubble Complexes: In Vitro and In Vivo Evaluations in a Prostate Cancer Model.
Bae YJ; Yoon YI; Yoon TJ; Lee HJ
Korean J Radiol; 2016; 17(4):497-508. PubMed ID: 27390541
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy priming of the Pancreatic Tumor Microenvironment Promotes Delivery and Anti-Metastasis Efficacy of Intravenous Low-Molecular-Weight Heparin-Coated Lipid-siRNA Complex.
Yu Q; Qiu Y; Chen X; Wang X; Mei L; Wu H; Liu K; Liu Y; Li M; Zhang Z; He Q
Theranostics; 2019; 9(2):355-368. PubMed ID: 30809279
[TBL] [Abstract][Full Text] [Related]
29. Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly.
Hu Q; Li W; Hu X; Hu Q; Shen J; Jin X; Zhou J; Tang G; Chu PK
Biomaterials; 2012 Sep; 33(27):6580-91. PubMed ID: 22717365
[TBL] [Abstract][Full Text] [Related]
30. Novel Survivin-Targeted Small Interfering RNA Delivered by Nanoparticles.
Feng C; Wang T; Zhang Y; Qu K; Tang S
Am J Med Sci; 2017 Nov; 354(5):506-512. PubMed ID: 29173363
[TBL] [Abstract][Full Text] [Related]
31. Topotecan and small interfering RNA suppress survivin expression synergistically in Caki-1 renal cancer cells: Direct suppression of survivin and enhancement of transfection efficiency by topotecan.
Sato A; Ito K; Asano T; Sumitomo M; Asano T; Hayakawa M
Int J Oncol; 2008 Jan; 32(1):171-6. PubMed ID: 18097556
[TBL] [Abstract][Full Text] [Related]
32. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells.
Su WP; Cheng FY; Shieh DB; Yeh CS; Su WC
Int J Nanomedicine; 2012; 7():4269-83. PubMed ID: 22904633
[TBL] [Abstract][Full Text] [Related]
33. Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel.
Liu C; Zhao G; Liu J; Ma N; Chivukula P; Perelman L; Okada K; Chen Z; Gough D; Yu L
J Control Release; 2009 Dec; 140(3):277-83. PubMed ID: 19699770
[TBL] [Abstract][Full Text] [Related]
34. Multifunctional Liposomes Enable Active Targeting and Twinfilin 1 Silencing to Reverse Paclitaxel Resistance in Brain Metastatic Breast Cancer.
Du J; Shao Y; Hu Y; Chen Y; Cang J; Chen X; Pei W; Miao F; Shen Y; Muddassir M; Zhang Y; Zhang J; Teng G
ACS Appl Mater Interfaces; 2021 May; 13(20):23396-23409. PubMed ID: 33982563
[TBL] [Abstract][Full Text] [Related]
35. Combination Nanopreparations of a Novel Proapoptotic Drug - NCL-240, TRAIL and siRNA.
Riehle R; Pattni B; Jhaveri A; Kulkarni A; Thakur G; Degterev A; Torchilin V
Pharm Res; 2016 Jul; 33(7):1587-601. PubMed ID: 26951567
[TBL] [Abstract][Full Text] [Related]
36. [Influence of short hairpin RNA on survivin mRNA expression and chemosensitivity to paclitaxel in ovarian cancer cells].
Yan XJ; Liang LZ; Zeng ZY; Fu LW; Shi Z
Zhonghua Fu Chan Ke Za Zhi; 2005 Sep; 40(9):609-13. PubMed ID: 16202317
[TBL] [Abstract][Full Text] [Related]
37. Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus.
Khan Z; Khan AA; Prasad GB; Khan N; Tiwari RP; Bisen PS
Radiother Oncol; 2016 Feb; 118(2):359-68. PubMed ID: 26747757
[TBL] [Abstract][Full Text] [Related]
38. Insights into the therapeutic potential of hypoxia-inducible factor-1α small interfering RNA in malignant melanoma delivered via folate-decorated cationic liposomes.
Chen Z; Zhang T; Wu B; Zhang X
Int J Nanomedicine; 2016; 11():991-1002. PubMed ID: 27042054
[TBL] [Abstract][Full Text] [Related]
39. [Cytological Study in vitro on Co-delivery of siRNA and Paclitaxel within Solid Lipid Nanoparticles to Overcome Multidrug Resistance in Tumors].
Huang R; Yao X; Chen Y; Sun X; Lin Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2016 Feb; 33(1):108-14. PubMed ID: 27382749
[TBL] [Abstract][Full Text] [Related]
40. Co-delivery of siRNA and hypericin into cancer cells by hyaluronic acid modified PLGA-PEI nanoparticles.
Li Y; Zhang J; Wang B; Shen Y; Ouahab A
Drug Dev Ind Pharm; 2016; 42(5):737-46. PubMed ID: 26472259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
